Peptide receptor radionuclide therapy (PRRT) uses radiolabeled peptides that bind to somatostatin receptors on neuroendocrine tumor cells, providing meaningful tumor shrinkage and symptom relief, though responses tend to be temporary.
177Lu-PRRTLutetium-177-labeled peptides have become the predominant form of peptide receptor radionuclide therapy, replacing earlier yttrium-90-based treatments
What the researchers found
PRRT using lutetium-177-labeled somatostatin analogs has become the dominant form of peptide-targeted radiation therapy for neuroendocrine tumors, replacing earlier yttrium-90-based approaches. The treatment achieves significant tumor control and symptom relief in patients with somatostatin receptor-positive neuroendocrine tumors.
However, as with other systemic therapies, treatment responses are relatively short-lived. The field is now focused on developing new peptides and treatment strategies, with a critical emphasis on individualizing therapy through patient-specific dosimetry — calculating radiation doses to both tumors and healthy organs — and understanding tissue-level radiosensitivity.
Why it matters
Neuroendocrine tumors are relatively rare cancers that can be difficult to treat with conventional therapies. PRRT represents one of the most successful examples of peptide-targeted therapy in oncology, using the tumor's own receptor biology against it. As the field moves toward personalized dosimetry, PRRT could become more effective and safer, potentially extending remissions and reducing side effects.
How the study worked
This is a review article that synthesizes the current state of PRRT for neuroendocrine tumors. The authors survey the evolution from yttrium-90 to lutetium-177 peptides, assess clinical outcomes, and discuss emerging strategies for treatment optimization including personalized dosimetry.
What this study cannot tell us
As a review article, this paper synthesizes existing evidence rather than presenting new experimental data. The abstract does not detail specific response rates, survival data, or comparative outcomes between yttrium-90 and lutetium-177 formulations. The short-lived nature of responses is acknowledged but specific durations are not provided.
How to read the evidence
This is a narrative review article published in a peer-reviewed journal. While it synthesizes clinical evidence on PRRT, it does not present new primary data or systematic analysis. Review articles provide valuable overviews but rank below randomized trials and systematic reviews in the evidence hierarchy.
When this study was published
Published in 2024, this review reflects the current state of PRRT for neuroendocrine tumors and is highly relevant to today's clinical practice and ongoing research directions.
The bigger picture
PRRT sits at the intersection of nuclear medicine and peptide science, showcasing how engineered peptides can serve as precision delivery vehicles for radiation therapy. The push toward individualized dosimetry reflects a broader trend in oncology toward precision medicine. Success with PRRT in neuroendocrine tumors has also inspired similar approaches for other receptor-positive cancers, expanding the role of radiolabeled peptides across oncology.
Questions still open
- How much can personalized dosimetry improve PRRT outcomes compared to current fixed-dose protocols?
- What new peptide formulations are showing the most promise in extending the duration of treatment response?
- Could combination approaches pairing PRRT with other systemic therapies overcome the problem of short-lived responses?
Common questions
What is peptide receptor radionuclide therapy (PRRT)?
Why did PRRT switch from yttrium-90 to lutetium-177?
Read the original research
Neuroendocrine Tumors: Beta Labeled Radiopeptides.
PET clinics, 19(3S), e1-e11
Citation
Bodei, Lisa; Jayaprakasam, Vetri Sudar; Ying Wong, Bernadette Zhi; Aparici, Carina Mari. (2024). Neuroendocrine Tumors: Beta Labeled Radiopeptides.. PET clinics, 19(3S), e1-e11. https://doi.org/10.1016/j.cpet.2024.06.003